Final Report of a Trial of Intensive versus Standard Blood-Pressure Control

RCT (n=9361) found among patients at increased CV risk, targeting systolic BP<120mmHg resulted in lower rates of major adverse CV events (1.77% vs. 2.40%/year; HR 0.73; 95% CI, 0.63-0.86) and lower all-cause mortality (1.06% vs. 1.41%/year;0.75; 0.61-0.92) than target of <140mmHg

New England Journal of Medicine